Currently, nine epigenetic agents are available in the US for treating cancer, including two DNA methyltransferase (DNMT) inhibitors (azacitidine and decitabine), four histone deacetylase (HDAC) inhibitors (vorinostat, romidepsin, belinostat, and panobinostat), two isocitrate dehydrogenase inhibitors (enasidenib and ivosidenib), and one EZH2 inhibitor (tazemetostatv) [10]. Here, DNMT1 is linked to cancer.